Cariprazine for the treatment of schizophrenia: A Review of this dopamine D3-Preferring D3/D2 receptor partial agonist

Clinical Schizophrenia and Related Psychoses

Volumn 10, Issue 2, 2016, Pages 109-119

  Citrome, Leslie ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antipsychotic; Cariprazine; Dopamine; Psychopharmacology; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; BREXPIPRAZOLE; CARIPRAZINE; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ILOPERIDONE; LURASIDONE; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

AKATHISIA; ANXIETY DISORDER; BINDING AFFINITY; BIPOLAR I DISORDER; BODY MASS; CAUCASIAN; CONSTIPATION; DISEASE EXACERBATION; DIZZINESS; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OBESITY; PHARMACODYNAMICS; PROTEIN BINDING; QT INTERVAL; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; VOMITING; WEIGHT GAIN; AGONISTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; PARTIAL AGONISM; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGONISTS; DRUG PARTIAL AGONISM; HUMANS; PIPERAZINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84984707010     PISSN: 19351232     EISSN: 19412010     Source Type: Journal    
DOI: 10.3371/1935-1232-10.2.109     Document Type: Review

References (33)

1. Actavis. VRAYLAR (cariprazine) capsules, for Oral use. Prescribing Information, Revised September 2015. Available from: http://www.allergan.com/assets/pdf/vraylar-pi [Last accessed 2016 March 6].
2. FDA. Cariprazine Drug Approval Package. Approval date 2015 September 17. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2015/204370Orig2s000TOC.cfm [Last accessed 2016 March 6].
3. Citrome L. The ABC's of dopamine receptor partial agonists - Aripiprazole, brexpiprazole and cariprazine: The 15-min challenge to sort these agents out. Int J Clin Pract 2015;69(11):1211-1220.
4. McEvoy J, Citrome L. Brexpiprazole for the treatment of schizophrenia: A review of this novel serotonin-dopamine activity modulator. Clin Schizophr Relat Psychoses 2016;9(4):177-186.
5. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: A systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2015;69(9):978-997.
6. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 2013;382(9896):951-962.
7. Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ, et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat 2015;11:3095-3104.
8. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10(12):1917-1928.
9. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther 2013;30(2):114-126.
10. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013;9(2):193-206.
11. Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics, G, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010;333(1):328-340.
12. Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl) 2013;226(1):91-100.
13. Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol 2016;26(1):3-14.
14. Gyertyán I, Kiss B, Sághy K, Laszy J, Szabo G, Szabados T, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 2011;59(6):925-935.
15. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006;5(1):25-43.
16. Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 2011;216(4):451-473.
17. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 2010;11(7):802-812.
18. Nakamura T, Kubota T, Iwakaji A, Imada M, Kapás M, Morio Y. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther 2016;10:327-338.
19. Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophr Res 2014;152(2-3):450-457.
20. Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- And active-controlled trial. J Clin Psychiatry 2015;76(12):e1574-e1582.
21. Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol 2015;35(4):367-373.
22. Durgam S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. Int Clin Psychopharmacol 2016;31(2):61-68.
23. Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2015;25(Suppl 2):S512-S513.
24. Debelle M, Németh G, Szalai E, Szatmari B, Harsányi J, Barabassy A, et al. Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: A double-blind, active controlled trial. Eur Neuropsychopharmacol 2015;25(Suppl 2):S510.
25. Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Res 2014;218(1-2): 219-224.
26. Durgam S, Nasrallah HA, Cutler AJ, Wang Y, Lu K, Nagy K, et al. Safety and tolerability of cariprazine in long-term treatment of schizophrenia: integrated summary of safety data. Int J Neuropsychopharmacol 2014;17(Suppl 1):68.
27. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother 2012;13(11):1599-1613.
28. Citrome L, Johnston S, Nadkarni A, Sheehan JJ, Kamat SA, Kalsekar I. Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychotics. Curr Drug Saf 2014;9(3):227-235.
29. Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry 2016;77(1):109-115.
30. Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: A phase II trial. Bipolar Disord 2015;17(1):63-75.
31. Calabrese JR, Keck PE Jr, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Efficacy and safety of low- And high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: A double-blind, placebo-controlled study. J Clin Psychiatry 2015;76(3):284-292.
32. Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, phase III trial. J Affect Disord 2015;174:296-302.
33. Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Nemeth G, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry 2016;173(3):271-281.